Phase 1 Clinical Trial to Evaluate the Safety of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis

NCT02221258 Phase 1 COMPLETED

The purpose of phase 1 clinical trial is to to evaluate safety in subjects with moderate to severe rheumatoid arthritis after infusion.

Details

Lead sponsor	Kang Stem Biotech Co., Ltd.
Phase	Phase 1
Status	COMPLETED
Enrolment	9
Start date	2014-10
Completion	2015-10

Conditions

• Rheumatoid Arthritis

Interventions

• FURESTEM-RA Inj.

Primary outcomes

• Safety of FURESTEM-RA Inj. treatment — 4 weeks follow-up after treatment
  Evaluate the number of adverse events, including clinically significant changes in physical examination, safety lab tests, ECG, vital signs

Countries

South Korea